lanthanum has been researched along with Renal Insufficiency, Chronic in 71 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (2.82) | 29.6817 |
| 2010's | 54 (76.06) | 24.3611 |
| 2020's | 15 (21.13) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, A; Xu, G; Zhao, L | 1 |
| Badve, SV; Block, GA; Elder, GJ; Hawley, CM; Johnson, DW; Lioufas, NM; Pascoe, EM; Toussaint, ND | 1 |
| Elder, GJ; Hawley, CM; Hewitson, TD; Holt, SG; Lioufas, NM; Pascoe, EM; Pedagogos, E; Smith, ER; Tiong, MK; Toussaint, ND; Valks, A | 1 |
| Achenbach, H; Murray, RA; Shavkin, A; Sundberg, A; Szabó, T; Uddin, S; Umeh, O; Vergani, A; Wasilewska, A | 1 |
| Bu, R; Gao, J; Han, R; Hao, J; Li, B; Li, G; Liu, H; Liu, Y; Sun, L; Wang, S; Zhao, J; Zhao, L | 1 |
| An, M; Bu, R; Cao, X; Gao, J; Gao, Y; Gu, C; Guo, M; Han, R; Hao, J; Li, B; Li, G; Liu, H; Liu, Y; Meng, Y; Su, C; Sun, L | 1 |
| Fukui, K; Gao, J; Hashimoto, A; Kanome, Y; Kohno, M; Nakatsu, M; Ogawa, Y | 1 |
| Chang, X; Li, M; Shang, S; Xu, W; Yu, M; Zhou, Q | 1 |
| Floege, J | 2 |
| Block, GA; Chertow, GM; Chonchol, M; de Boer, IH; Ginsberg, C; Hoofnagle, A; Kestenbaum, B; Zelnick, LR | 1 |
| Choukroun, G; Couchoud, C; Jacquelinet, C; Lambert, O; Mercadal, L; Metzger, M | 1 |
| Jiang, J; Li, Y; Liu, G; Wang, Z; Zheng, D; Zhou, H | 1 |
| Badve, SV; Block, GA; Boudville, N; Cameron, JD; Campbell, KL; Chen, SSM; Elder, GJ; Faull, RJ; Hawley, CM; Holt, SG; Hooi, LS; Jackson, D; Jardine, MJ; Johnson, DW; Kerr, PG; Lau, KK; Lioufas, NM; Narayan, O; Pascoe, EM; Pedagogos, E; Perkovic, V; Polkinghorne, KR; Pollock, CA; Reidlinger, D; Robison, L; Smith, ER; Toussaint, ND; Valks, A; Walker, RJ; Wang, AYM | 1 |
| Chonchol, MB; Gassman, J; Ginsberg, C; Ix, JH; Jamshidian, MS; Larive, B; Raphael, KL | 1 |
| Akizawa, T; Fukagawa, M; Fukushima, M; Hirakata, H; Kagimura, T; Ogata, H | 1 |
| Cardone, KE; Hudson, JQ; St. Peter, WL; Wazny, LD; Weinhandl, E | 1 |
| Fujii, H; Goto, S; Kono, A; Kono, K; Nakai, K; Nishi, S; Nishii, T | 1 |
| Wang, S; Zhang, C; Zhang, X; Zhao, S | 1 |
| Garg, AX; Habbous, S; Martin, J; Przech, S; Sarma, S | 1 |
| Hasegawa, M; Hayashi, H; Inaguma, D; Ito, E; Koide, S; Takahashi, K; Yuzawa, Y | 1 |
| Carfagna, F; Del Vecchio, L; Locatelli, F; Pontoriero, G | 1 |
| Gao, Y; Li, Y; Lv, C; Wang, G; Wang, Z | 1 |
| Badve, SV; Elder, G; Hawley, C; Lioufas, N; Pascoe, E; Pedagogos, E; Toussaint, ND; Valks, A | 1 |
| Block, GA; Cheung, AK; Flessner, MF; Fried, LF; Gassman, JJ; Isakova, T; Ix, JH; Larive, B; Middleton, JP; Raj, DS; Raphael, KL; Sprague, SM; Wolf, M | 1 |
| Badve, SV; Toussaint, ND; Yeung, WG | 1 |
| Fujii, H; Goto, K; Goto, S; Kono, K; Nishi, S; Watanabe, K | 1 |
| Barchi-Chung, A; Contreras, G; Diego, J; Dosch, A; Enfield, G; Gutiérrez, OM; Houston, J; Isakova, T; Lenz, O; Mendez, A; Schiavenato, E; Smith, K; Vargas, G; Wahl, P; Weiner, RB; Wolf, M; Xie, H | 1 |
| Inaba, M; Ito, A; Nitta, K; Otsubo, S; Satoh, S; Tanaka, M; Tominaga, Y; Yajima, A | 1 |
| Fukagawa, M; Koizumi, M; Komaba, H | 1 |
| Bierhals, AJ; Cheng, SC; Dávila-Román, VG; de las Fuentes, L; Dietzen, DJ; Hruska, KA; Ross, W; Rothstein, M; Seifert, ME; Windus, D | 1 |
| Kimura, K; Oishi, D; Sakurada, T; Shibagaki, Y; Yasuda, T | 1 |
| Fan, J; Li, Z; Wen, J; Zhang, C | 1 |
| Behets, GJ; D'Haese, PC; Damment, SJ; Dams, G; De Broe, ME; Martin, P | 1 |
| Goumenos, DS; Papachristou, E; Sonikian, M | 1 |
| Adema, AY; de Borst, MH; Ter Wee, PM; Vervloet, MG | 1 |
| Del Vecchio, L; Locatelli, F | 1 |
| Wada, K; Wada, Y | 1 |
| Agapova, O; Fang, Y; Freedman, BI; Ginsberg, C; Hruska, KA; Malluche, H; Monier-Faugere, MC; Register, TC; Seifert, M; Sugatani, T | 1 |
| Kong, XL; Li, WB; Wang, ZS; Wei, Y | 1 |
| Copley, JB; Keddad, K; Preston, P; Prié, D; Ureña-Torres, P; Wan, H; Wilde, P | 1 |
| Matsuda, Y; Shigematsu, T; Takahara, Y; Takahashi, S | 1 |
| Anderson, CA; Block, GA; Ix, JH; Persky, MS; Smits, G | 1 |
| Sun, J; Wang, R; Yang, XW; Zhai, CJ | 1 |
| Kawaguchi, K; Kodama, R; Makino, M; Nagasawa, M; Nakamura, H; Shimojo, H | 1 |
| Kitazono, T; Noguchi, H; Ooboshi, H; Tatsumoto, N; Tokumoto, M; Tsuruya, K; Yamada, S | 1 |
| Imanishi, Y; Inaba, M; Ishimura, E; Nagayama, H; Okuno, S; Shoji, S; Yamada, S | 1 |
| Hanafusa, N | 1 |
| Suzuki, H; Takenaka, T; Yamanaka, T; Yoshida, M | 1 |
| Beaubien-Souligny, W; Bell, R; Bezzaoucha, S; Lafrance, JP; Lamarche, C; Ouimet, D; Pichette, V; Vallee, M | 1 |
| Lederer, SR; Schmid, H | 1 |
| Garg, AX; Habbous, S; Martin, J | 1 |
| Gutekunst, L | 1 |
| Akizawa, T; Fukagawa, M; Hirakata, H; Kagimura, T; Kaneda, H; Ogata, H | 1 |
| Craig, JC; French, R; Gardner, S; Johnson, DW; Mavridis, D; Palmer, SC; Ruospo, M; Strippoli, GF; Tonelli, M | 1 |
| Acedillo, R; Garg, AX; Habbous, S; Martin, J; Przech, S; Sarma, S | 1 |
| Anderson, CA; Nguyen, HA; Rifkin, DE | 1 |
| Chang, YM; Chen, IL; Hsu, KS; Huang, YT; Jhen, RN; Kao, JL; Liou, HH; Liu, MC; Shiao, CC; Tsai, SC; Tung, NY; Yang, CL | 1 |
| Craig, JC; Elder, GJ; Navaneethan, SD; Palmer, SC; Strippoli, GF | 1 |
| Laville, M | 1 |
| Benchitrit, J; Drüeke, TB; Edelman, A; Guerrera, IC; Joki, N; Jorgetti, V; Lacour, B; Machado dos Reis, L; Maizel, J; Massy, ZA; Nguyen-Khoa, T; Nikolov, IG | 1 |
| Brunner-Ziegler, S; Fröschl, B; Hiebinger, C; Zsifkovits, J | 1 |
| Moe, SM; Moorthi, RN | 1 |
| Drüeke, TB; Massy, ZA | 1 |
| Allison, MA; Asplin, J; Block, GA; Chertow, GM; Hoofnagle, AN; Kestenbaum, B; Ketteler, M; Kooienga, L; Mannstadt, M; Persky, MS; Smits, G; Spiegel, DM; Thadhani, R; Wheeler, DC; Wolf, M | 1 |
| Chiyotanda, S; Fujimoto, S; Fukudome, K; Kitamura, K; Sato, Y; Toida, T; Yamada, K | 1 |
| Bruschetta, E; Cozzolino, M; Cusi, D; Galassi, A; Giovenzana, ME; Montanari, E | 1 |
| Evenepoel, P; Meijers, B | 1 |
| Chen, JH; Chen, XM; Ding, GH; Fan, YP; Liu, ZH; Mei, CL; Ni, ZH; Wang, LN; Wang, M; Xu, J; Yu, XQ; Yuan, FH; Zhang, AP; Zhang, YX | 1 |
| Aljama, P; Almadén, Y; Martín-Malo, A; Ojeda, R; Rodríguez, M; Soriano, S | 1 |
| Akizawa, T; Kinugasa, E; Koiwa, F; Ogata, H | 1 |
23 review(s) available for lanthanum and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
Topics: Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hyperphosphatemia; Lanthanum; Observational Studies as Topic; Parathyroid Hormone; Phosphates; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sevelamer; Treatment Outcome | 2021 |
Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD.
Topics: Chelating Agents; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Renal Insufficiency, Chronic; Sevelamer | 2022 |
Phosphate binders in chronic kidney disease: an updated narrative review of recent data.
Topics: Chelating Agents; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer | 2020 |
A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
Topics: Calcium Compounds; Chelating Agents; Drug Costs; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Meta-Analysis as Topic; Phosphates; Renal Insufficiency, Chronic; Sevelamer | 2017 |
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
Topics: Adult; Aged; Calcium Carbonate; Chelating Agents; Cost-Benefit Analysis; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sevelamer | 2018 |
Current and potential treatment options for hyperphosphatemia.
Topics: Animals; Chelating Agents; Drug Design; Humans; Hyperphosphatemia; Iron; Lanthanum; Phosphates; Renal Insufficiency, Chronic; Sevelamer | 2018 |
Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
Topics: Animals; Binding, Competitive; Bone and Bones; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Progression; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Gene Expression Regulation; Glucuronidase; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Kidney Tubules; Klotho Proteins; Lanthanum; Models, Biological; Parathyroid Glands; Parathyroid Hormone; Phosphates; Polyamines; Receptor, Fibroblast Growth Factor, Type 1; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency | 2013 |
Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review.
Topics: China; Chronic Kidney Disease-Mineral and Bone Disorder; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Humans; Incidence; Lanthanum; Male; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Optimal use of phosphate binders in chronic kidney disease.
Topics: Aluminum Hydroxide; Calcium Compounds; Chelating Agents; Humans; Hyperphosphatemia; Lanthanum; Magnesium; Patient Compliance; Phosphates; Polyamines; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Sevelamer; Vascular Calcification | 2013 |
Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
Topics: Calcium; Calcium, Dietary; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Diet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Naphthalenes; Phosphorus; Phosphorus, Dietary; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2014 |
Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis.
Topics: Bone Density; Calcium; Calcium Carbonate; Chelating Agents; Humans; Hypercalcemia; Lanthanum; Parathyroid Hormone; Phosphorus; Radiography; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Vascular Calcification | 2015 |
Restoration of parathyroid function after change of phosphate binder from calcium carbonate to lanthanum carbonate in hemodialysis patients with suppressed serum parathyroid hormone.
Topics: Calcium Carbonate; Female; Humans; Lanthanum; Male; Middle Aged; Parathyroid Glands; Parathyroid Hormone; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic | 2015 |
[Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of phosphate binders on vascular calcification].
Topics: Bone Diseases, Metabolic; Calcium; Cardiovascular Diseases; Chelating Agents; Drug Discovery; Humans; Hyperphosphatemia; Japan; Lanthanum; Polyamines; Prognosis; Renal Insufficiency, Chronic; Sevelamer; Vascular Calcification | 2015 |
Novel iron-containing phosphate binders for treatment of hyperphosphatemia.
Topics: Animals; Carbonates; Clinical Trials as Topic; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Lanthanum; Magnesium; Phosphates; Renal Insufficiency, Chronic; Sevelamer; Starch; Sucrose | 2015 |
Phosphate binders in chronic kidney disease: a systematic review of recent data.
Topics: Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer; Sucrose | 2016 |
An Update on Phosphate Binders: A Dietitian's Perspective.
Topics: Aluminum Hydroxide; Calcium Carbonate; Diet; Dose-Response Relationship, Drug; Humans; Hyperphosphatemia; Lanthanum; Nutritionists; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic | 2016 |
Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials.
Topics: Adult; Chelating Agents; Humans; Lanthanum; Network Meta-Analysis; Phosphates; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sevelamer | 2016 |
The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
Topics: Biomarkers; Calcium Compounds; Chelating Agents; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Renal Insufficiency, Chronic; Safety; Sevelamer; Treatment Outcome | 2017 |
Nutrition Interventions in Chronic Kidney Disease.
Topics: Body Weight; Calcium Carbonate; Cardiovascular Diseases; Chelating Agents; Diet; Diet, Mediterranean; Dyslipidemias; Exercise; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperglycemia; Lanthanum; Phosphorus, Dietary; Protein-Energy Malnutrition; Renal Insufficiency, Chronic; Sodium, Dietary; Water-Electrolyte Balance | 2016 |
Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Topics: Acetates; Biomarkers; Bone Density Conservation Agents; Calcium; Calcium Carbonate; Calcium Compounds; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hypercalcemia; Hyperphosphatemia; Lanthanum; Parathyroid Hormone; Phosphates; Phosphorus; Polyamines; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Research Design; Sevelamer | 2009 |
[Efficacy and safety of lanthanum carbonate in chronic kidney disease patients with hyperphosphataemia].
Topics: Humans; Hyperphosphatemia; Lanthanum; Renal Insufficiency, Chronic | 2011 |
Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate.
Topics: Animals; Bone Diseases, Metabolic; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Lanthanum; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic | 2012 |
CKD-MBD: impact on management of kidney disease.
Topics: Aniline Compounds; Bone Diseases, Metabolic; Calcium Metabolism Disorders; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Naphthalenes; Phenethylamines; Polyamines; Propylamines; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency; Vitamins | 2007 |
25 trial(s) available for lanthanum and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Effect of lanthanum carbonate on serum calciprotein particles in patients with stage 3-4 CKD-results from a placebo-controlled randomized trial.
Topics: Aged; Calcium Phosphates; Female; Humans; Lanthanum; Male; Middle Aged; Pulse Wave Analysis; Renal Dialysis; Renal Insufficiency, Chronic | 2023 |
An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis.
Topics: Adolescent; Child; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2022 |
Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease.
Topics: Acetates; Aged; Calcium Compounds; Chelating Agents; Double-Blind Method; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphates; Prognosis; Renal Insufficiency, Chronic; Sevelamer; Vitamin D | 2020 |
A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
Topics: Aged; Aorta, Abdominal; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Pulse Wave Analysis; Renal Insufficiency, Chronic; Tomography, X-Ray Computed; Vascular Calcification | 2020 |
Effect of Lanthanum Carbonate on Blood Pressure in CKD.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Drug Interactions; Female; Humans; Hypertension; Intestinal Absorption; Lanthanum; Male; Middle Aged; Phosphates; Renal Insufficiency, Chronic | 2021 |
Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
Topics: Aged; Calcium Carbonate; Cardiovascular Diseases; Female; Heart Disease Risk Factors; Hip Fractures; Humans; Hyperparathyroidism; Hyperphosphatemia; Incidence; Japan; Lanthanum; Male; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Survival Analysis; Vascular Calcification | 2021 |
Effect of lanthanum carbonate on coronary artery calcification and bone mineral density in maintenance hemodialysis patients with diabetes complicated with adynamic bone disease: A prospective pilot study.
Topics: Administration, Oral; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases; Calcinosis; Calcium Carbonate; Coronary Artery Disease; Diabetes Complications; Female; Fibroblast Growth Factor-23; Humans; Lanthanum; Male; Middle Aged; Pilot Projects; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2017 |
Effect of combined vitamin D receptor activator and lanthanum carbonate on serum fibroblast growth factor 23 level in predialysis patients (CVD-LAF study): design and method.
Topics: Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hydroxycholecalciferols; Lanthanum; Receptors, Calcitriol; Renal Dialysis; Renal Insufficiency, Chronic; Research Design | 2018 |
Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease.
Topics: Administration, Oral; Adult; Aged; Biomarkers; Calcium Carbonate; Charcoal; Chelating Agents; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphates; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Vascular Calcification | 2019 |
Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
Topics: Adult; Cardiovascular Diseases; Clinical Protocols; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Male; Parathyroid Hormone; Phosphates; Renal Insufficiency, Chronic | 2019 |
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
Topics: Adult; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; Humans; Lanthanum; Male; Middle Aged; Monte Carlo Method; Niacinamide; Phosphates; Renal Insufficiency, Chronic; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2019 |
Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.
Topics: Adult; Aged; Chelating Agents; Combined Modality Therapy; Down-Regulation; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Florida; Humans; Lanthanum; Least-Squares Analysis; Male; Middle Aged; Phosphates; Phosphorus, Dietary; Renal Insufficiency, Chronic; Single-Blind Method; Time Factors; Treatment Outcome | 2013 |
Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Diabetes Complications; Double-Blind Method; Feasibility Studies; Female; Homeostasis; Humans; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Phosphorus, Dietary; Pilot Projects; Renal Insufficiency, Chronic; Risk Factors; Treatment Outcome; Vascular Stiffness | 2013 |
Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders.
Topics: Adult; Animals; Calcium; Carbamates; Cellulose; Chelating Agents; Female; Gastrointestinal Tract; Humans; Lanthanum; Male; Phosphates; Polyamines; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Sevelamer; Young Adult | 2014 |
Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial.
Topics: Aged; Aortic Diseases; Calcinosis; Calcium Carbonate; Chelating Agents; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Tomography, X-Ray Computed | 2014 |
CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.
Topics: Adaptor Proteins, Signal Transducing; Adult; Animals; Bone Diseases, Metabolic; Bone Morphogenetic Proteins; Disease Models, Animal; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glucuronidase; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Klotho Proteins; Lanthanum; Male; Mice, Inbred C57BL; Phosphates; Phosphorus, Dietary; Renal Insufficiency, Chronic; Wnt1 Protein | 2014 |
Effect of calcium carbonate combined with calcitonin on hypercalcemia in hemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; Calcitonin; Calcium; Calcium Carbonate; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Young Adult | 2014 |
Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Lanthanum; Male; Middle Aged; Phosphorus; Placebo Effect; Reference Values; Renal Insufficiency, Chronic; Treatment Outcome | 2014 |
Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Chelating Agents; Double-Blind Method; Female; Humans; Hyperphosphatemia; Intention to Treat Analysis; Japan; Lanthanum; Male; Middle Aged; Phosphates; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2014 |
Design and baseline characteristics of the LANDMARK study.
Topics: Aged; Biomarkers; Calcium Carbonate; Cardiovascular Diseases; Chelating Agents; Clinical Protocols; Disease-Free Survival; Female; Humans; Hyperphosphatemia; Japan; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Research Design; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients.
Topics: Aged; Biomarkers; Calcium Carbonate; Chelating Agents; Down-Regulation; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Hepcidins; Humans; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus, Dietary; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Taiwan; Time Factors; Treatment Outcome | 2017 |
Effects of phosphate binders in moderate CKD.
Topics: Acetates; Aged; Aged, 80 and over; Bone Density; Calcium Compounds; Chelating Agents; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Pilot Projects; Polyamines; Renal Insufficiency, Chronic; Sevelamer; Vascular Calcification | 2012 |
Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
Topics: Acid Phosphatase; Aged; Alkaline Phosphatase; Analysis of Variance; Calcium; Calcium Carbonate; Chelating Agents; Chi-Square Distribution; Cross-Over Studies; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hypercalcemia; Hyperphosphatemia; Isoenzymes; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Tartrate-Resistant Acid Phosphatase; Vitamin D | 2012 |
Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China.
Topics: Adolescent; Adult; Aged; China; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Prevalence; Renal Insufficiency, Chronic; Risk Assessment; Treatment Outcome; Young Adult | 2013 |
The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Calcium Carbonate; Chelating Agents; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Renal Insufficiency, Chronic; Statistics, Nonparametric; Vitamin D | 2013 |
23 other study(ies) available for lanthanum and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Lanthanum hydroxide inhibits vascular calcification by regulating the HIF-1 pathway.
Topics: Animals; Cardiovascular Diseases; Lanthanum; Phosphorus; Rats; Renal Insufficiency, Chronic; Vascular Calcification | 2022 |
Metabolomics of clinical samples reveal the treatment mechanism of lanthanum hydroxide on vascular calcification in chronic kidney disease.
Topics: Amino Acid Transport Systems, Neutral; Humans; Kidney Failure, Chronic; Lanthanum; Metabolomics; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Renal Insufficiency, Chronic; TOR Serine-Threonine Kinases; Vascular Calcification | 2022 |
Evaluation of cerium oxide as a phosphate binder using 5/6 nephrectomy model rat.
Topics: Animals; Cerium; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Nephrectomy; Phosphates; Phosphorus; Rats; Renal Insufficiency, Chronic | 2022 |
A 47-Year-Old Man with Hyperphosphatemia Due to Chronic Renal Failure Treated with Lanthanum Carbonate Tablets Presenting Acutely with Partial Large Bowel Obstruction.
Topics: Humans; Hyperphosphatemia; Intestinal Obstruction; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Tablets | 2023 |
Effects of the dialysate calcium concentrations and mineral bone disease treatments on mortality in The French Renal Epidemiology and Information Network (REIN) registry.
Topics: Aged; Blood Vessels; Bone and Bones; Calcinosis; Calcium; Cinacalcet; Female; France; Hemodialysis Solutions; Humans; Lanthanum; Longitudinal Studies; Male; Middle Aged; Proportional Hazards Models; Registries; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Vitamin D | 2020 |
Fortified phosphorus‑lowering treatment through administration of lanthanum protects against vascular calcification via regulation of FGF23 in chronic kidney disease.
Topics: Animals; Blood Urea Nitrogen; Calcium; Creatinine; Disease Models, Animal; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Kidney; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Protective Agents; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Vascular Calcification | 2020 |
Effects of Lanthanum Carbonate on Coronary Artery Calcification and Cardiac Abnormalities After Initiating Hemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Calcium Carbonate; Chelating Agents; Coronary Vessels; Female; Fibroblast Growth Factor-23; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Vascular Calcification | 2018 |
Dual Inhibition of Gastrointestinal Phosphate Absorption: More Questions Than Answers.
Topics: Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Niacinamide; Phosphates; Renal Insufficiency, Chronic | 2019 |
Effects of lanthanum carbonate on bone markers and bone mineral density in incident hemodialysis patients.
Topics: Aged; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Calcium; Calcium Carbonate; Female; Humans; Lanthanum; Male; Middle Aged; Osteocalcin; Parathyroid Hormone; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Tartrate-Resistant Acid Phosphatase | 2019 |
Impact of lanthanum carbonate on cortical bone in dialysis patients with adynamic bone disease.
Topics: Aged; Bone and Bones; Bone Diseases; Dose-Response Relationship, Drug; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic | 2013 |
Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients.
Topics: Administration, Oral; Aged; Calcium; Female; Humans; Lanthanum; Male; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Tablets; Treatment Outcome | 2013 |
Optimal phosphate control: still an unmet need in chronic kidney disease patients.
Topics: Humans; Hyperphosphatemia; Lanthanum; Parathyroid Hormone; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2014 |
Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover study.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Circadian Rhythm; Cross-Over Studies; Diet; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; Healthy Volunteers; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Renal Insufficiency, Chronic | 2014 |
Extensive lanthanum deposition in the gastric mucosa: the first histopathological report.
Topics: Adenocarcinoma; Breast Neoplasms; Female; Gastric Mucosa; Humans; Hyperphosphatemia; Lanthanum; Microscopy, Electron, Scanning; Middle Aged; Neoplasms, Second Primary; Renal Insufficiency, Chronic; Spectrometry, X-Ray Emission; Stomach Neoplasms | 2015 |
Phosphate binders prevent phosphate-induced cellular senescence of vascular smooth muscle cells and vascular calcification in a modified, adenine-based uremic rat model.
Topics: Adenine; Animal Feed; Animals; Calcinosis; Calcium Carbonate; Cellular Senescence; Disease Models, Animal; Disease Progression; Fibrosis; Immunohistochemistry; Inflammation; Kidney; Kidney Failure, Chronic; Lanthanum; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxidative Stress; Phosphates; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Signal Transduction; Uremia; Vascular Calcification | 2015 |
Unexpected action of lanthanum carbonate.
Topics: Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Renal Insufficiency, Chronic | 2015 |
The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D.
Topics: Acidosis; Bicarbonates; Canada; Chelating Agents; Disease Progression; Drug Monitoring; Female; Humans; Hyperphosphatemia; Kidney Function Tests; Lanthanum; Male; Middle Aged; Nutritional Status; Patient Acuity; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome | 2015 |
Appraisal of a redundant report on lanthanum carbonate.
Topics: Chelating Agents; Humans; Lanthanum; Renal Insufficiency, Chronic; Vascular Calcification | 2016 |
Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice.
Topics: Analysis of Variance; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Blood Chemical Analysis; Bone Density; Collagen; Disease Models, Animal; Disease Progression; Female; Immunohistochemistry; Lanthanum; Mice; Mice, Inbred Strains; Polyamines; Random Allocation; Reference Values; Renal Insufficiency, Chronic; Sevelamer; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Uremia; Vascular Calcification | 2012 |
Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
Topics: Adult; Aged; Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cost Savings; Health Care Costs; Hemodialysis Solutions; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Parathyroid Hormone; Phosphorus; Polyamines; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Technology Assessment, Biomedical | 2011 |
CKD-mineral and bone disorder: core curriculum 2011.
Topics: Bone Diseases; Calcinosis; Calciphylaxis; Calcitriol; Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney; Kidney Failure, Chronic; Kidney Tubules; Lanthanum; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Polyamines; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Vitamin D | 2011 |
Phosphate binders in CKD: bad news or good news?
Topics: Acetates; Calcium Compounds; Chelating Agents; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2012 |
Chronic kidney disease: Phosphate binder therapy--cracks in the tower of strength?
Topics: Acetates; Blood Vessels; Calcinosis; Calcium Compounds; Chelating Agents; Disease Progression; Humans; Hyperphosphatemia; Lanthanum; Phosphate-Binding Proteins; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2012 |